VDAC1 and hepatocellular carcinoma: In combination with ZZW-115, we used L-Buthionine-(S,R)-Sulfoximine BSO, a specific GCLC inhibitor; Erastin, a small molecule capable of initiating ferroptotic cell death by activating the Voltage-Dependent Anion Channels (VDAC); and RSL3, a ferroptosis activator in a VDAC-independent manner as a proof-of-concept, to treat PDAC- and HCC-derived cells.